Compare AMST & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMST | AEON |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.6M |
| IPO Year | 2020 | N/A |
| Metric | AMST | AEON |
|---|---|---|
| Price | $2.12 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 492.9K | 167.7K |
| Earning Date | 02-09-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $193,505.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 68.56 | N/A |
| 52 Week Low | $2.00 | $0.38 |
| 52 Week High | $5.18 | $45.29 |
| Indicator | AMST | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 59.04 |
| Support Level | $2.05 | $0.72 |
| Resistance Level | $2.75 | $1.12 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 7.89 | 77.53 |
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.